Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their observational study, Dr Eisenstein and colleagues1 suggest that extended use of clopidogrel in patients with DES may be associated with a reduced risk of myocardial infarction and mortality. Although the authors do not explicitly advocate that clopidogrel be used indefinitely in patients with DES, they comment that their findings support the Clopidogrel for the Reduction of Events During Observation (CREDO) trial,2 which in turn advocates that all patients with DES should continue to take clopidogrel for at least 12 months and possibly indefinitely.
Falcone EL, Tangri N. Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation. JAMA. 2007;297(16):1769-1771. doi:10.1001/jama.297.16.1770-b